Cheng Zhou

1.4k total citations
51 papers, 1.1k citations indexed

About

Cheng Zhou is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Cheng Zhou has authored 51 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 16 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Cheng Zhou's work include MicroRNA in disease regulation (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Cheng Zhou is often cited by papers focused on MicroRNA in disease regulation (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Cheng Zhou collaborates with scholars based in China, Ethiopia and Hong Kong. Cheng Zhou's co-authors include Jia Fan, Bao‐Ye Sun, Bailin Zhang, Minggao Guo, Ming He, Guoqiang Chen, Yong Yi, Qiang Zhao, Jian Zhou and Zhangfu Yang and has published in prestigious journals such as Oncogene, Biochemical and Biophysical Research Communications and International Journal of Molecular Sciences.

In The Last Decade

Cheng Zhou

50 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cheng Zhou China 17 583 436 250 179 145 51 1.1k
Wenwei Zhu China 11 650 1.1× 422 1.0× 318 1.3× 239 1.3× 141 1.0× 19 1.1k
Leyuan Zhou China 15 843 1.4× 762 1.7× 288 1.2× 259 1.4× 124 0.9× 37 1.3k
Rifat Hasina United States 19 612 1.0× 275 0.6× 326 1.3× 139 0.8× 218 1.5× 38 1.1k
Shanglei Ning China 16 695 1.2× 400 0.9× 329 1.3× 186 1.0× 100 0.7× 28 1.2k
Miryam Müller Germany 11 598 1.0× 448 1.0× 251 1.0× 151 0.8× 70 0.5× 15 965
Gang Xiao China 20 501 0.9× 209 0.5× 376 1.5× 197 1.1× 148 1.0× 63 1.1k
Aeree Kim South Korea 20 548 0.9× 264 0.6× 444 1.8× 171 1.0× 109 0.8× 42 1.0k

Countries citing papers authored by Cheng Zhou

Since Specialization
Citations

This map shows the geographic impact of Cheng Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng Zhou more than expected).

Fields of papers citing papers by Cheng Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng Zhou. The network helps show where Cheng Zhou may publish in the future.

Co-authorship network of co-authors of Cheng Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng Zhou. A scholar is included among the top collaborators of Cheng Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng Zhou. Cheng Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guan, Ruo‐Yu, Zhangfu Yang, Bao‐Ye Sun, et al.. (2024). Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis. Cancer Medicine. 13(23). e70459–e70459. 1 indexed citations
2.
Zhou, Cheng, et al.. (2024). ANP32B inhibition suppresses the growth of prostate cancer cells by regulating c-Myc signaling. Biochemical and Biophysical Research Communications. 698. 149543–149543. 1 indexed citations
3.
4.
Zhou, Cheng, et al.. (2024). USP54 is a potential therapeutic target in castration-resistant prostate cancer. BMC Urology. 24(1). 32–32. 1 indexed citations
5.
Zhou, Cheng, Bao‐Ye Sun, Yong Yi, et al.. (2024). Peripheral Lymphocytes in Primary Liver Cancers: Elevated NK and CD8+ T Cells and Dysregulated Selenium Metabolism. Biomolecules. 14(2). 222–222. 5 indexed citations
6.
Zhou, Cheng, et al.. (2023). Identification of molecular subtypes and a prognostic signature based on chromatin regulators related genes in prostate cancer. Frontiers in Genetics. 13. 1110723–1110723. 4 indexed citations
7.
Zhou, Cheng, Bao‐Ye Sun, Pei‐Yun Zhou, et al.. (2023). MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway. Clinical Immunology. 256. 109770–109770. 20 indexed citations
8.
Sun, Bao‐Ye, Zhangfu Yang, Zhu-Tao Wang, et al.. (2023). Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma. World Journal of Surgical Oncology. 21(1). 90–90. 13 indexed citations
9.
Yang, Hainan, Lei Wen, Chao Zhao, et al.. (2022). EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome. Frontiers in Oncology. 12. 902664–902664. 6 indexed citations
10.
11.
Guan, Ruo‐Yu, Bao‐Ye Sun, Zhu-Tao Wang, et al.. (2022). Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. The American Journal of Surgery. 224(1). 494–500. 5 indexed citations
12.
Yi, Yong, Bao‐Ye Sun, Jialei Weng, et al.. (2022). Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study. Frontiers in Oncology. 12. 1046584–1046584. 21 indexed citations
13.
Liu, Gao, Jian Sun, Zhangfu Yang, et al.. (2021). Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis. Cell Death and Disease. 12(3). 260–260. 95 indexed citations
14.
Zhou, Cheng, et al.. (2020). <p><em>miR-602</em> Mediates the RASSF1A/JNK Pathway, Thereby Promoting Postoperative Recurrence in Nude Mice with Liver Cancer</p>. OncoTargets and Therapy. Volume 13. 6767–6776. 9 indexed citations
15.
Zhou, Cheng, et al.. (2020). <p>PFND1 Predicts Poor Prognosis of Gastric Cancer and Promotes Cell Metastasis by Activating the Wnt/β-Catenin Pathway</p>. OncoTargets and Therapy. Volume 13. 3177–3186. 12 indexed citations
16.
Zhang, Yuan, Xiaohan Wei, Cheng Zhou, et al.. (2020). Jianpi Huayu Decoction Attenuates the Immunosuppressive Status of H22 Hepatocellular Carcinoma-Bearing Mice: By Targeting Myeloid-Derived Suppressor Cells. Frontiers in Pharmacology. 11. 16–16. 26 indexed citations
17.
18.
Liu, Wenya, et al.. (2014). Rare reason for pulmonary embolism: one case of pulmonary hydatid cyst and review of the literature. Journal of Thrombosis and Thrombolysis. 40(1). 126–129. 6 indexed citations
19.
Zhang, Bailin, Cheng Zhou, Minggao Guo, et al.. (2010). Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 32(1). 2–9. 186 indexed citations
20.
Chen, Min, Tiemei Zhang, Senlin Luo, et al.. (2007). Functional magnetic resonance imaging and immunohistochemical study of hypothalamic function following oral glucose ingestion in rats. Chinese Medical Journal. 120(14). 1232–1235. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wenwei Zhu Breakdown of academic impact, for papers by Leyuan Zhou Breakdown of academic impact, for papers by Rifat Hasina Breakdown of academic impact, for papers by Shanglei Ning Breakdown of academic impact, for papers by Miryam Müller Breakdown of academic impact, for papers by Gang Xiao Breakdown of academic impact, for papers by Aeree Kim
Rankless by CCL
2026